ArticlePrzeglad gastroenterologiczny2025

One-year single-center follow-up study of ustekinumab and vedolizumab use in inflammatory bowel disease Egyptian patients as second-line therapy after anti-TNF failure.

Shimaa Kamel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.